# US 2008/0214518 A1 · Pharmaceutical Composition Comprising an Anti-Bacterial Agent and an Active Ingredient Selected From Carveol, Thymol, Eugenol, Borneol and Carvacrol > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2008/0214518 A1 - Document ID: US20080214518A1 - Status: Published application - Kind: A1 - Application number: 11/914,015 - Filed: 2006-05-15 - Published: 2008-09-04 - Earliest claimed: 2005-05-13 - Assignees: Advanced Scientific Developments - Inventors: Adnane Remmal - Web page: https://patentgrep.com/patent/US20080214518A1 ## CPC - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates - A61K 31/05: Phenols {(cannabinoids A61K31/658)} - A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 31/04: Antibacterial agents - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The invention relates to a pharmaceutical composition comprising at least one first active therapeutic substance selected among carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone, as well as isomers, derivatives and mixtures thereof, and comprising at least one second active therapeutic substance that is an antibiotic. ## Claims ### Claim at position 1 1-13. (canceled) ### Claim 14 A pharmaceutical composition comprising: at least one first therapeutically active substance selected from the group consisting of carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone, and isomers, derivatives or mixtures thereof; and at least one second therapeutically active substance which is an antibiotic selected from the group consisting of beta-lactams, cephalosporins, tetracyclines, rifamycins, peptides, amino sides, phenicols, macrolides, and derivatives or mixtures thereof. ### Claim 15 (depends on 14) The composition according to claim 14, wherein said second therapeutically active substance is selected from the group consisting of amoxicillin, amoxicillin in association with clavulanic acid, ampicillin, streptomycin, erythromycin, polymyxin B, chloramphenicol, tetracycline, chlortetracycline, rifampicin, isoniazide, cephazolin, and derivatives or mixtures thereof. ### Claim 16 (depends on 14) The composition according to claim 14, wherein said first therapeutically active substance is selected from the group consisting of carvacrol, carveol, thymol, alpha-ionone and beta-ionone and said second therapeutically active substance is selected from the group consisting of amoxicillin, amoxicillin in association with clavulanic acid, ampicillin, streptomycin, erythromycin, polymyxin B, chloramphenicol, tetracycline, chlortetracycline, rifampicin, isoniazide, cephazolin, and derivatives or mixtures thereof. ### Claim 17 (depends on 16) The composition according to claim 16, wherein said first therapeutically active substance is carveol or carvacrol and second therapeutically active substance is selected from the group consisting of amoxicillin, ampicillin, chloramphenicol, tetracycline, chlortetracycline, streptomycin, erythromycin, polymyxin B, rifampicin, amoxicillin in association with clavulanic acid, and derivatives and mixtures thereof. ### Claim 18 (depends on 17) The composition according to claim 17, wherein said first therapeutically active substance is carveol and second therapeutically active substance is amoxicillin. ### Claim 19 (depends on 16) The composition according to claim 16, wherein said first therapeutically active substance is alpha-ionone or beta-ionone and second therapeutically active substance is cephazolin. ### Claim 20 (depends on 16) The composition according to claim 16, wherein said first therapeutically active substance is thymol and said second therapeutically active substance is isoniazide. ### Claim 21 (depends on 16) The composition according to claim 16, wherein said first and second therapeutically active substances are suspended in an aqueous agar solution. ### Claim 22 (depends on 16) The composition according to claim 16, wherein said composition does not include any detergent or solvent. ### Claim 23 A kit comprising: at least one first container containing a first therapeutically active substance selected from the group consisting of carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone and isomers, derivatives or mixtures thereof; and at least one second container containing a second therapeutically active substance which is an antibiotic selected from the group consisting of beta-lactams, cephalosporins, tetracyclines, rifamycins, peptides, aminosides, phenicols, macrolides and derivatives or mixtures thereof. ### Claim 24 (depends on 23) The kit according to claim 23, wherein said second therapeutically active substance selected from the group consisting of amoxicillin, amoxicillin in association with clavulanic acid, ampicillin, streptomycin, erythromycin, polymyxin B, chloramphenicol, tetracycline, chlortetracycline, rifampicin, isoniazide, cephazolin, and derivatives or mixtures thereof. ### Claim 25 (depends on 23) The kit according to claim 23, wherein said first therapeutically active substance is selected from the group consisting of carvacrol, carveol, thymol, alpha-ionone and beta-ionone and said second therapeutically active substance is selected from the group consisting of amoxicillin, amoxicillin in association with clavulanic acid, ampicillin, streptomycin, erythromycin, polymyxin B, chloramphenicol, tetracycline, chlortetracycline, rifampicin, isoniazide, cephazolin, and derivatives or mixtures thereof. ### Claim 26 (depends on 25) The kit according to claim 25, wherein said first therapeutically active substance is carveol or carvacrol and said second therapeutically active substance is selected from the group consisting of amoxicillin, ampicillin, chloramphenicol, tetracycline, chlortetracycline, streptomycin, erythromycin, polymyxin B, rifampicin, amoxicillin in association with clavulanic acid, and derivatives or mixtures thereof. ### Claim 27 (depends on 26) The kit according to claim 26, wherein said first therapeutically active substance is carveol and said second therapeutically active substance is amoxicillin. ### Claim 28 (depends on 25) The kit according to claim 25, wherein said first therapeutically active substance is alpha-ionone or beta-ionone and said second therapeutically active substance is cephazolin. ### Claim 29 (depends on 25) The kit according to claim 25, wherein said first therapeutically active substance is thymol and said second therapeutically active substance is isoniazide. ### Claim 30 A method for treating an infection caused by bacteria comprising the simultaneous or sequential administration to a patient of: at least one first therapeutically active substance selected from the group consisting of carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone, and isomers, derivatives or mixtures thereof, and at least one second therapeutically active substance which is an antibiotic selected from the group consisting of the beta-lactams, cephalosporins, tetracyclines, rifamycins, peptides, amino sides, phenicols, macrolides and derivatives or mixtures thereof. ### Claim 31 (depends on 30) The method according to claim 30, wherein said first therapeutically active substance is selected from the group consisting of carvacrol, carveol, thymol, alpha-ionone and beta-ionone, and said second therapeutically active substance is selected from the group consisting of amoxicillin, amoxicillin in association with clavulanic acid, ampicillin, streptomycin, erythromycin, polymyxin B, chloramphenicol, tetracycline, chlortetracycline, rifampicin, isoniazide, cephazolin, and derivatives or mixtures thereof. ### Claim 32 (depends on 31) The method according to claim 31, wherein said first therapeutically active substance is carveol or carvacrol and said second therapeutically active substance is selected from the group consisting of amoxicillin, ampicillin, chloramphenicol, tetracycline, chlortetracycline, streptomycin, erythromycin, polymyxin B, rifampicin, amoxicillin in association with clavulanic acid, and derivatives or mixtures thereof. ### Claim 33 (depends on 32) The method according to claim 32, wherein said first therapeutically active substance is carveol and said second therapeutically active substance is amoxicillin. ### Claim 34 (depends on 31) The method according to claim 31, wherein said first therapeutically active substance is alpha-ionone or beta-ionone and said second therapeutically active substance is cephazolin. ### Claim 35 (depends on 31) The method according to claim 31, wherein said first therapeutically active substance is thymol and said second therapeutically active substance is isoniazide. ### Claim 36 (depends on 30) The method according to claim 30, wherein said method comprises simultaneously or sequentially administering to a patient: between 10 and 200 mg/kg of body weight/day of said first therapeutically active substance; and between 2 and 100 mg/kg of body weight/day of said second therapeutically active substance.